SCYNEXIS Proprietary and Confidential Information SCYX-6759, an Orally Bioavailable Oxaborole 6-carboxamide, Achieves Therapeutically Relevant Exposure in Brain and CSF Leading to 100% Cures in a Mouse Model of CNS-stage Human African Trypanosomiasis Stephen Wring , Bakela Nare, Cyrus Bacchi, Beth Beaudet, Tana Bowling, Daitao Chen, Robert Don, Yvonne Freund, Eric Gaukel, Kurt Jarnagin, Matthew Jenks, Luke Mercer, Andy Noe, Matthew Orr, Robin Parham, Jacob Plattner, Cindy Rewerts, Jessica Sligar, Nigel Yarlett, and Robert Jacobs. [email protected]Scynexis Inc., Research Triangle Park, Durham, NC27709
14
Embed
SCYNEXIS Proprietary and Confidential Information SCYX-6759, an Orally Bioavailable Oxaborole 6-carboxamide, Achieves Therapeutically Relevant Exposure.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SCYNEXIS Proprietary and Confidential Information
SCYX-6759, an Orally Bioavailable Oxaborole 6-carboxamide, Achieves Therapeutically
Relevant Exposure in Brain and CSF Leading to 100% Cures in a Mouse Model of CNS-stage
Human African TrypanosomiasisStephen Wring, Bakela Nare, Cyrus Bacchi, Beth Beaudet, Tana
Bowling, Daitao Chen, Robert Don, Yvonne Freund, Eric Gaukel, Kurt Jarnagin, Matthew Jenks, Luke Mercer, Andy Noe, Matthew Orr,
Robin Parham, Jacob Plattner, Cindy Rewerts, Jessica Sligar, Nigel Yarlett, and Robert Jacobs.
Dose Response in Murine Model of CNS HAT ( Day 147 Update)
0 20 40 60 80 100 120 1400
20
40
60
80
100
Berenil D4
Berenil D216759-6mg/kg
6759-12.5 mg/kg6759-25 mg/kg6759-50 mg/kg
Days Post-infection
% A
nim
als
Par
asit
e F
ree
OB
ON
OCF3
F
SCYX-6759
b.i.d. (Q12hr) PO
SCYNEXIS Proprietary and Confidential Information
Dose Response in Murine Model of CNS HAT ( Day 147 Update)
0 20 40 60 80 100 120 1400
20
40
60
80
100
Berenil D4
Berenil D217158-6mg/kg
7158-12.5 mg/kg
7158-25 mg/kg7158-50 mg/kg
Days Post-infection
% A
nim
als
Par
asit
e F
ree
0 20 40 60 80 100 120 1400
20
40
60
80
100
Berenil D4
Berenil D216759-6mg/kg
6759-12.5 mg/kg6759-25 mg/kg6759-50 mg/kg
Days Post-infection
% A
nim
als
Par
asit
e F
ree
0 10 20 30 40 50
0
20
40
60
80
100
SCYX-6759
SCYX-7158
Oral Dose (mg/kg)
% A
nim
als
Par
asit
e F
ree
at D
ay 1
33 P
ost
-tre
atm
ent
OB
ON
OCF3
F
OB
ON
OCF3
F
SCYX-7158 SCYX-6759
b.i.d. (Q12hr) POq.d. PO
Poster #829: Jacobs, B. et alSession C, Exhibit Hall A, Noon- 1.30pm
SCYNEXIS Proprietary and Confidential Information
Conclusions
●SCYX-6759:♦ Discovered by a collaboration of DNDi, Anacor, PACE
University and Scynexis.♦ A new class of anti-trypanosomal drug.♦ Achieved 100% efficacy in a murine stage 2 HAT model.♦ Readily crosses the blood-brain and blood-testicular
barriers.♦ Efficacy can be predicted from brain exposure.♦ Led to SCYX-7158 - a pre-clinical candidate for HAT.
SCYNEXIS Proprietary and Confidential Information
Acknowledgments
●Multi-center collaboration:♦ DNDi♦ Scynexis Inc.♦ Anacor Pharmaceuticals Inc.♦ Pace University - Haskins lab.♦ Swiss Tropical Institute